<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556608</url>
  </required_header>
  <id_info>
    <org_study_id>06CZIFCH/Hai06</org_study_id>
    <nct_id>NCT00556608</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis</brief_title>
  <official_title>Efficacy Evaluation of Intra-articular Hyaluronic Acid (Sinovial®) vs Synvisc® in the Treatment of Symptomatic Knee Osteoarthritis. A Double-blind, Controlled, Randomised, Parallel-group Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove the non-inferiority of the intra-articular injection of
      hyaluronic acid (Sinovial®) in the symptomatic treatment of knee OA in comparison to
      Synvisc®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in WOMAC pain subscore from baseline</measure>
    <time_frame>to week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC OA Index total score and pain, function and stiffness subscores;Change in Lequesne's algofunctional index; Change in global pain (visit assessment); Change in global status by the patient;Change in global status by the Investigator;SPID%</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">381</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Sinovial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 intra-articular injections of Sinovial®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinvisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinovial® (syringe containing sodium hyaluronate solution)</intervention_name>
    <description>2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.</description>
    <arm_group_label>Sinovial</arm_group_label>
    <other_name>Sinovial®: Class III medical device(CE mark n° 0499)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synvisc® ( syringe containing Hylan G-F 20 solution)</intervention_name>
    <description>2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.</description>
    <arm_group_label>Sinvisc</arm_group_label>
    <other_name>Synvisc®: class III medical device (CE mark n° 0088)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 40 and 80 years

          -  Primary knee OA of the medial or lateral femoro-tibial compartment

          -  Symptoms for at least 3 months

          -  Diagnosis according to ACR criteria

          -  Kellgren &amp; Lawrence radiological grade 2-3

          -  Patients who failed to respond sufficiently (not responders) to analgesics and/or
             NSAIDs taken regularly or responders intolerant to the regular use of analgesics
             and/or NSAIDs.

          -  Mean WOMAC pain subscore at the target knee &gt;= 40 mm and &lt; 80 mm on a VAS at baseline
             after wash-out from analgesics/NSAIDs· If bilateral knee OA: definition of the most
             symptomatic joint at screening based on patient's evaluation and Investigator's
             clinical judgment and mean WOMAC pain subscore at baseline in the contra-lateral knee
             &lt; 30 mm

          -  Written informed consent

          -  Subject able to understand, co-operative and reliable

        Exclusion Criteria:

          -  BMI &gt;= 32 kg/m2

          -  Secondary (post-traumatic) knee OA

          -  Predominantly patello-femoral pain/syndrome

          -  No remaining joint space width

          -  Symptomatic hip OA or other interfering health condition

          -  Severe varus/valgus deformity (&gt;15°)

          -  History/present evidence of (target knee): inflammatory, infective or metabolic joint
             diseases; recurrent clinical chondrocalcinosis; crystal arthropaties; osteo-articular
             pathologies differing from arthrosis; articular fracture; ochronosis; acromegaly;
             haemochromatosis; Wilson's disease; primary osteochondromatosis; heritable disorders;
             collagen gene mutations.

          -  Concomitant rheumatic disease

          -  Significant injury to the target knee in the last 6 months

          -  Previous joint replacement/arthroplasty (target knee)

          -  Arthroscopy/osteotomy/surgery in the past 1 year (target knee)

          -  Any surgery scheduled in the next 6 months

          -  Venous or lymphatic stasis in the relevant limb

          -  Skin infection/disease/trauma at the injection site

          -  Systemic or i.a. (target knee) corticosteroids in the past 3 months

          -  I.a. corticosteroids (non-target joint) in the past 4 weeks

          -  Viscosupplementation (target knee) in the past year

          -  Recently started (in the last 3 months) physical therapy (target knee)

          -  Recently (in the last 3 months) started therapy or change in dosage of SYSADOAs

          -  Ongoing anticoagulant therapy

          -  Chronic or recurrent use of NSAIDs/analgesics/narcotics because of diseases different
             from OA of the target knee

          -  History of allergy or hypersensitivity to hyaluronic acid or paracetamol or avian
             proteins

          -  Participation in a clinical study in the last 3 months

          -  Pregnant or lactating women, and women of childbearing potential not willing to use
             adequate contraception

          -  Patients unable to stay in the study for 6 months, non-cooperating, not able to
             understand
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karel PAVELKA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Rheumatology-Na Slupi 4 - 12850 Praha 2 (Czech Republic)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Interni hemato-onkologická klinika, Fakultní nemocnice</name>
      <address>
        <city>Brno - Bohunice</city>
        <zip>63900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTHROMED s.r.o.</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Praha</city>
        <zip>12850</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum léčby pohybového aparátu spol. s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>19061</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre Bois-Guillaume</name>
      <address>
        <city>Bois Guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Centre of Limoges - Rheumatology Service</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Universitätsklinik und Poliklinik der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova clinic</name>
      <address>
        <city>Biberach an der Riss</city>
        <zip>88400</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Praxis</name>
      <address>
        <city>Stockach</city>
        <zip>78333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione Dipartimentale a valenza provinciale di Reumatologia - AzUSL 8</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Privato Accreditato Nigrisoli</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina e Traumatologia dello Sport - AzUSL 2 Lucca</name>
      <address>
        <city>Lucca</city>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Reumatologia - Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit Santa Chiara Hospital</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Reumatologia - Az. Ospedaliera Universitaria Senese - Policlinico &quot;Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>F.D. Roosevelt's University Hospital</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Romjan s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>831 03</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Rheumatic Diseases</name>
      <address>
        <city>Piest'any</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic, Reumaglobal s.r.o</name>
      <address>
        <city>Trnava</city>
        <zip>917 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology and Institute of Physical Medicine - Zurich University</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Theiler R, Brühlmann P. Overall tolerability and analgesic activity of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis. Curr Med Res Opin. 2005 Nov;21(11):1727-33.</citation>
    <PMID>16307692</PMID>
  </reference>
  <reference>
    <citation>Castellacci E, Polieri T. Antalgic effect and clinical tolerability of hyaluronic acid in patients with degenerative diseases of knee cartilage: an outpatient treatment survey. Drugs Exp Clin Res. 2004;30(2):67-73.</citation>
    <PMID>15272644</PMID>
  </reference>
  <reference>
    <citation>Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 Dec;62(12):1145-55. Review.</citation>
    <PMID>14644851</PMID>
  </reference>
  <reference>
    <citation>Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000 Sep;43(9):1905-15.</citation>
    <PMID>11014340</PMID>
  </reference>
  <reference>
    <citation>Altman RD. Status of hyaluronan supplementation therapy in osteoarthritis. Curr Rheumatol Rep. 2003 Feb;5(1):7-14. Review.</citation>
    <PMID>12590879</PMID>
  </reference>
  <reference>
    <citation>Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA. 2003 Dec 17;290(23):3115-21.</citation>
    <PMID>14679274</PMID>
  </reference>
  <reference>
    <citation>Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am. 2004 Mar;86-A(3):538-45.</citation>
    <PMID>14996880</PMID>
  </reference>
  <reference>
    <citation>Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005321. Review.</citation>
    <PMID>16625635</PMID>
  </reference>
  <reference>
    <citation>Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis. 1996 Aug;55(8):552-7.</citation>
    <PMID>8774185</PMID>
  </reference>
  <reference>
    <citation>Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, Buckwalter J, Dougados M, Ehrlich G, Lequesne M, Lohmander S, Murphy WA Jr, Rosario-Jansen T, Schwartz B, Trippel S. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage. 1996 Dec;4(4):217-43.</citation>
    <PMID>11048620</PMID>
  </reference>
  <reference>
    <citation>Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials. Curr Rheumatol Rep. 2004 Feb;6(1):20-30. Review.</citation>
    <PMID>14713399</PMID>
  </reference>
  <reference>
    <citation>Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006 Feb;14(2):154-62. Epub 2005 Oct 19.</citation>
    <PMID>16242361</PMID>
  </reference>
  <reference>
    <citation>Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988 Dec;15(12):1833-40.</citation>
    <PMID>3068365</PMID>
  </reference>
  <reference>
    <citation>Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol. 2002 Dec;29(12):2473-6. Review.</citation>
    <PMID>12465137</PMID>
  </reference>
  <reference>
    <citation>KELLGREN JH, LAWRENCE JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957 Dec;16(4):494-502.</citation>
    <PMID>13498604</PMID>
  </reference>
  <reference>
    <citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug;29(8):1039-49.</citation>
    <PMID>3741515</PMID>
  </reference>
  <reference>
    <citation>Lockman LE. Practice tips. Knee joint injections and aspirations: the triangle technique. Can Fam Physician. 2006 Nov;52(11):1403-4.</citation>
    <PMID>17279197</PMID>
  </reference>
  <reference>
    <citation>Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation--value in comparison with other assessment tests. Scand J Rheumatol Suppl. 1987;65:85-9. Erratum in: Scand J Rheumatol Suppl 1988;73:1. Scand J Rheumatol 1988;17(3):following 241.</citation>
    <PMID>3479839</PMID>
  </reference>
  <reference>
    <citation>Lequesne M, Samson M, Gérard P, Mery C. [Pain-function indices for the follow-up of osteoarthritis of the hip and the knee]. Rev Rhum Mal Osteoartic. 1990 Oct 30;57(9 ( Pt 2)):32S-36S. French.</citation>
    <PMID>2080414</PMID>
  </reference>
  <reference>
    <citation>Ali Y, Weinstein M, Jokl P. Acute pseudogout following intra-articular injection of high molecular weight hyaluronic acid. Am J Med. 1999 Dec;107(6):641-2.</citation>
    <PMID>10625037</PMID>
  </reference>
  <reference>
    <citation>Luzar MJ, Altawil B. Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum. 1998 May;41(5):939-40.</citation>
    <PMID>9588748</PMID>
  </reference>
  <reference>
    <citation>Maillefert JF, Hirschhorn P, Pascaud F, Piroth C, Tavernier C. Acute attack of chondrocalcinosis after an intraarticular injection of hyaluronan. Rev Rhum Engl Ed. 1997 Oct;64(10):593-4.</citation>
    <PMID>9385702</PMID>
  </reference>
  <reference>
    <citation>Allen E, Krohn K. Adverse reaction to Hylan GF-20. J Rheumatol. 2000 Jun;27(6):1572.</citation>
    <PMID>10852302</PMID>
  </reference>
  <reference>
    <citation>Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee : a report of six cases. J Bone Joint Surg Am. 2002 Jul;84-A(7):1142-7.</citation>
    <PMID>12107313</PMID>
  </reference>
  <reference>
    <citation>Zardawi IM, Chan I. Synvisc perisynovitis. Pathology. 2001 Nov;33(4):519-20.</citation>
    <PMID>11827424</PMID>
  </reference>
  <reference>
    <citation>Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003 Apr;32(5):296-309. Review.</citation>
    <PMID>12701040</PMID>
  </reference>
  <reference>
    <citation>Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000 Nov;27(11):2635-41.</citation>
    <PMID>11093446</PMID>
  </reference>
  <reference>
    <citation>Angst F, Aeschlimann A, Michel BA, Stucki G. Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol. 2002 Jan;29(1):131-8.</citation>
    <PMID>11824949</PMID>
  </reference>
  <reference>
    <citation>Bijlsma JW. Patient centred outcomes in osteoarthritis. Ann Rheum Dis. 2005 Jan;64(1):1-2.</citation>
    <PMID>15608297</PMID>
  </reference>
  <reference>
    <citation>Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis. 2005 Jan;64(1):29-33. Epub 2004 Jun 18.</citation>
    <PMID>15208174</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>December 3, 2012</last_update_submitted>
  <last_update_submitted_qc>December 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

